FDA 483 - Takeda Pharmaceutical Company Limited - September 15, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Takeda Pharmaceutical Company Limited in Round Lake, IL, revealed three significant observations. The firm failed to microbiologically test incoming bulk albumin for objectionable organisms, did not thoroughly review unexplained discrepancies and batch failures related to endotoxin, and exhibited deficiencies in validating supplier test results and auditing contract laboratories for critical utilities. These issues highlight concerns in quality control and supplier oversight for a licensed biological drug manufacturer.
ID · 4e49acd1-ce68-49ee-bfe4-8266281bdf7c